Atsena Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy Designation for ATSN-201 Gene Therapy To Treat X-Linked Retinoschisis
UF startup Atsena Therapeutics announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy designation for ATSN-201 for the treatment of X-linked retinoschisis.
Atsena Therapeutics Announces Oversubscribed $150 Million Series C Financing To Further Advance Ocular Gene Therapy Programs
UF startup Atsena Therapeutics, a clinical-stage gene therapy company focused on reversing or preventing blindness, announced the successful close of an oversubscribed $150 million Series C financing round.
Atsena Therapeutics Granted U.S. FDA Fast Track Designation for ATSN-201 Gene Therapy To Treat X-Linked Retinoschisis
UF startup Atsena Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ATSN-201 for the treatment of X-linked retinoschisis (XLRS).
Atsena Therapeutics Initiates Part B of Phase I/II Clinical Trial Evaluating Gene Therapy ATSN-201 To Treat X-Linked Retinoschisis
UF startup Atsena Therapeutics, a clinical-stage gene therapy company specializing in genetic medicine to reverse or prevent blindness, has announced the initiation of Part B of the LIGHTHOUSE study, a Phase I/II clinical trial evaluating the subretinal injection of ATSN-201 for treating XLRS.
Atsena Therapeutics Announces Dosing Completed in Part A of Phase I/II Clinical Trial Evaluating Gene Therapy ATSN-201 To Treat X-Linked Retinoschisis
UF startup Atsena Therapeutics announced dosing has been completed in Part A of the LIGHTHOUSE study, a Phase I/II clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS).
How Atsena Got Its Gene Therapy To Spread Subretinally To Treat XLRS
UF researcher Sanford Boye, co-founder and adviser of UF Startup Atsena Therapeutics, shared insights into how the company developed its gene therapy to achieve subretinal spread for treating XLRS.
Atsena Therapeutics and Nippon Shinyaku Enter Exclusive License Agreement for ATSN-101
Atsena Therapeutics Inc., a UF Startup, has entered into an exclusive license agreement with Nippon Shinyaku Co., Ltd. for the commercialization of ATSN-101 in the United States, and for its development and commercialization in Japan.
Gene Therapy Restores Vision in First-Ever Trial for Rare, Inherited Blindness
A gene therapy developed by University of Florida scientists, which restored useful vision to most patients with the rare, inherited blindness known as Leber congenital amaurosis type I, or LCA1, in a small trial.
Atsena Therapeutics Receives Rare Pediatric Disease Designation From the U.S. FDA for ATSN-201 Gene Therapy To Treat X-Linked Retinoschisis
UF startup Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation (RPD) for ATSN-201 for the treatment of X-linked retinoschisis (XLRS).
First Cohort Benefits From Atsena Therapeutics XLRS Gene Therapy
UF startup Atsena Therapeutics has announced positive preliminary data for its gene therapy candidate ATSN-201 for the treatment of X-linked retinoschisis (XLRS).
